| BMO's Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly |
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to the departure of Novo Nordisk's CEO, what is means for the company's trajectory, and more. |
youtube.com |
2025-05-16 16:29:35 |
Czytaj oryginał (ang.) |
| Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash |
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development. |
seekingalpha.com |
2025-05-16 15:50:54 |
Czytaj oryginał (ang.) |
| Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share |
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has failed to impress investors. |
nypost.com |
2025-05-16 15:43:16 |
Czytaj oryginał (ang.) |
| Why Novo Nordisk Stock Just Slipped |
Novo Nordisk (NVO -4.34%) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from his role as CEO in "mutual agreement" with the company's board. |
fool.com |
2025-05-16 15:07:16 |
Czytaj oryginał (ang.) |
| Novo Nordisk CEO to step down, citing market challenges |
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss a new leadership shakeup at drug-maker Novo Nordisk. |
youtube.com |
2025-05-16 15:02:51 |
Czytaj oryginał (ang.) |
| Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price |
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. |
investors.com |
2025-05-16 15:00:47 |
Czytaj oryginał (ang.) |
| SPX 6000 Close? Plus, NVO CEO Out, CAVA Dip and Buffett's STZ Position |
Kevin Green joins Morning Trade Live as markets open mixed to begin Friday's trading. For the intraday S&P 500 (SPX) ranges KG is watching, he points to 5960-5970 for upward resistance. |
youtube.com |
2025-05-16 14:21:03 |
Czytaj oryginał (ang.) |
| Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do? |
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs. |
zacks.com |
2025-05-16 14:11:09 |
Czytaj oryginał (ang.) |
| Novo Nordisk Stock Suffers After C-Suite Shakeup |
Novo Nordisk A/S (NYSE:NVO) is down 3.9% to trade at $63.60 this morning, after a C-suite shakeup. |
schaeffersresearch.com |
2025-05-16 13:59:02 |
Czytaj oryginał (ang.) |
| Novo Nordisk CEO to step down after eight years at the helm |
Novo Nordisk (NYSE:NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years leading the Danish pharmaceutical giant, known for its blockbuster obesity and diabetes drugs Wegovy and Ozempic. The company said on Friday the decision was made by mutual agreement with the company's board amid recent market challenges, including increased competition and a significant decline in the company's share price since mid-2024. |
proactiveinvestors.com |
2025-05-16 13:35:05 |
Czytaj oryginał (ang.) |
| Novo Nordisk CEO to step down amid pressure from obesity drug competition |
Novo Nordisk (NYSE:NVO) has announced that chief executive Lars Fruergaard Jørgensen will step down after eight years in the role, as the company contends with growing pressure in the obesity treatment market. The Danish pharmaceutical group, best known for its Wegovy weight-loss drug, said Jørgensen would stay on temporarily to support a smooth leadership transition. |
proactiveinvestors.co.uk |
2025-05-16 13:25:59 |
Czytaj oryginał (ang.) |
| Talks to replace Novo Nordisk CEO lasted several weeks, board chair says |
Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ongoing for the past few weeks, the company's board Chair Helge Lund told Reuters on Friday. |
reuters.com |
2025-05-16 13:17:53 |
Czytaj oryginał (ang.) |
| Instant View: Wegovy-maker Novo Nordisk ousts CEO as competition in obesity drug market heats up |
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. |
reuters.com |
2025-05-16 12:21:31 |
Czytaj oryginał (ang.) |
| Novo Nordisk CEO to step down as competition weighs on Wegovy maker's share price |
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news from Novo Nordisk. |
youtube.com |
2025-05-16 11:59:19 |
Czytaj oryginał (ang.) |
| Ozempic maker Novo Nordisk boots CEO over stock-price fall |
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday. |
marketwatch.com |
2025-05-16 11:37:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk CEO to Step Down Amid Market Challenges |
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership. |
wsj.com |
2025-05-16 11:25:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk |
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. |
globenewswire.com |
2025-05-16 11:19:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk's CEO to step down as competition weighs on Wegovy maker's share price |
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership." |
cnbc.com |
2025-05-16 11:12:22 |
Czytaj oryginał (ang.) |
| Novo Nordisk CEO to step down |
Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down. |
reuters.com |
2025-05-16 11:07:06 |
Czytaj oryginał (ang.) |
| Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months |
Bad news keeps coming for Novo Nordisk (NVO 2.58%). The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer. |
fool.com |
2025-05-16 08:47:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S – NVO |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ:NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-27 22:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132828&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 20:30:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman |
SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. |
globenewswire.com |
2025-02-27 20:14:00 |
Czytaj oryginał (ang.) |
| Shareholders of Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132801&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 18:15:00 |
Czytaj oryginał (ang.) |
| NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers. |
globenewswire.com |
2025-02-27 18:00:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion |
Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2025-02-27 17:53:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline - NVO |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132777&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 15:25:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. |
globenewswire.com |
2025-02-27 14:42:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132734&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 12:30:00 |
Czytaj oryginał (ang.) |
| NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-02-27 12:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132686&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 11:45:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser |
SAN FRANCISCO, CA / ACCESS Newswire / February 27, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NVO) who purchased or otherwise acquired Novo securities between November 2, 2022, and December 19, 2024, inclusive (the "Class Period") to contact us immediately regarding a pending securities class action against Novo. |
accessnewswire.com |
2025-02-27 11:10:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S |
Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 27 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. |
globenewswire.com |
2025-02-27 11:03:00 |
Czytaj oryginał (ang.) |
| Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why. |
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NVO -1.54%) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years. |
fool.com |
2025-02-27 09:45:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO |
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-02-27 07:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132577&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 22:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ:NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-26 22:00:00 |
Czytaj oryginał (ang.) |
| Investors who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky about Pending Class Action - NVO |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=132532&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 20:30:00 |
Czytaj oryginał (ang.) |
| ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-02-26 19:58:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join – Contact The Gross Law Firm |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). |
globenewswire.com |
2025-02-26 15:32:00 |
Czytaj oryginał (ang.) |
| What's Going on With Novo Nordisk Stock? |
Novo Nordisk (NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes. |
fool.com |
2025-01-05 07:23:00 |
Czytaj oryginał (ang.) |
| Better Buy: Novo Nordisk vs. AstraZeneca |
Novo Nordisk (NVO 0.15%) and AstraZeneca (AZN 0.56%) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't know it by looking at their stock market performances. |
fool.com |
2025-01-04 07:42:00 |
Czytaj oryginał (ang.) |
| Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz |
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year |
youtube.com |
2025-01-03 14:06:01 |
Czytaj oryginał (ang.) |
| Novo Resources to Trade on the OTCQB Market |
VANCOUVER, British Columbia, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (TSX: NVO) (ASX: NVO) (OTCQB: NSRPF) announces that it has transitioned its trading platform from the OTCQX to the OTCQB market in the United States. |
globenewswire.com |
2025-01-02 14:20:00 |
Czytaj oryginał (ang.) |
| Should You Buy the Dip in Novo Nordisk Stock Right Now? |
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chronic weight management, although research suggests these medications could have other applications in areas such as sleep apnea, kidney disease, and cardiovascular complications. |
fool.com |
2025-01-02 10:30:00 |
Czytaj oryginał (ang.) |
| Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-01 12:51:12 |
Czytaj oryginał (ang.) |
| Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock |
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-01-01 12:25:27 |
Czytaj oryginał (ang.) |
| Novo Nordisk: Be Greedy When Others Are Fearful |
Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin. Despite competition from Eli Lilly and short-term manufacturing limitations, NVO retains a strong market position in a high-growth industry, with P/E multiples poised to expand. My valuation model projects a $134.60 price target for December 2026, reflecting a Strong Buy with significant upside potential and a core allocation of 17.5% in my portfolio. |
seekingalpha.com |
2025-01-01 05:11:11 |
Czytaj oryginał (ang.) |
| Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better |
With only one trading day left in 2024, the S&P 500 Index is up approximately 23%. However, as investors look back on the year, they'll see a textbook example of why the stock market is a poor proxy for the economy, which has delivered unclear and, in some cases, conflicting data points. |
marketbeat.com |
2024-12-31 11:01:51 |
Czytaj oryginał (ang.) |
| Why Novo Nordisk (NVO) Dipped More Than Broader Market Today |
In the most recent trading session, Novo Nordisk (NVO) closed at $85.73, indicating a -1.88% shift from the previous trading day. |
zacks.com |
2024-12-30 20:50:24 |
Czytaj oryginał (ang.) |
| My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks |
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is not a get-rich-quick strategy, it requires commitment and a long-term mindset. Making a New Year's resolution is a great way to help maintain that mindset. I discuss two scenarios of hypothetical investors who start their journey in 2025. I detail the significant impact a long-term commitment – even without additional investments – can make. |
seekingalpha.com |
2024-12-30 12:00:38 |
Czytaj oryginał (ang.) |
| Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst |
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. "This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. |
youtube.com |
2024-12-29 11:00:09 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Be Monster Winners in 2025 |
What do many kids like most about the coming of a new year? The fireworks. |
fool.com |
2024-12-29 08:47:00 |
Czytaj oryginał (ang.) |
| Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders |
If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors. |
fool.com |
2024-12-29 07:39:00 |
Czytaj oryginał (ang.) |
| Is Eli Lilly Stock a Buy? |
While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself "Ozempic Santa," he wasn't taking Ozempic. |
fool.com |
2024-12-29 06:35:00 |
Czytaj oryginał (ang.) |
| 2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades |
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory. |
fool.com |
2024-12-28 08:05:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 |
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side-effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Headwinds While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones being: A 2017 $59 million fine from the DOJ due to lack of FDA disclosures concerning cancer risks from diabetes drug Victoza; Membership suspension from the UK’s Association of British Pharmacy Industry over ethics violations tantamount to bribing of health professionals; 235 active Ozempic related product liability lawsuits as of August, 2024; A 2024 investigation led by the US Senate confirmed predatory pricing of Ozempic by almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over the next 1, 5, to 10 years. While most Wall Street analysts will calculate 12-month forward projections, it’s clear that nobody has a consistent crystal ball, and plenty of unforeseen circumstances can render even near-term projections irrelevant. 24/7 Wall Street aims to present some farther-looking insights based on Novo Nordisk’s own numbers, along with business and market development information that may be of help to our readers’ own research. Key Points In This Article Novo Nordisk’s R&D is heavily invested in improved obesity treatments Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has Amycretin in FDA phase-1 and CagriSegma in phase-2 trials, which both show greater efficacy potential than Wegovy and Ozempic. Although the number of Ozempic-related lawsuits are piling up, Novo Nordisk’s stance is that the complaints are unwarranted, and will either be dismissed or settled. Novo Nordisk’s past acquisitions for both greater production capacity and logistical flexibility will reap benefits through geopolitical risk mitigation and broader product menu options. Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. Novo Nordisk News and Updates 12/20/2024 Novo Nordisk’s stock price plummeted by as much as 24% today. This was due to disappointing late-stage trial results for its experimental weight-loss drug, CagriSema. 12/18/2024 Novo Nordisk has partnered with Photys Therapeutics to develop a novel therapeutic targeting an undisclosed cardiometabolic disease. The partnership leverages Photy’s proprietary PHICS technology, which holds promise for addressing unmet medical needs in the cardiometabolic field. 12/16/2024 Novo Nordisk announced a large investment of $1.2 billion to build a new production facility in Denmark. The new state-of-the-art facility, located in Odense, will focus on manufacturing medications for rare diseases. 12/13/2024 A recent study published on medRxiv, though not yet peer-reviewed, suggests a possible link between Novo Nordisk’s weight-loss drug Ozempic and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). This finding also aligns with research from Harvard University earlier this year. 12/12/2024 Novo Nordisk has received European approval for a new indication of its drug, Ozempic. The European Medicines Agency (EMA) has authorized a label expansion to include the treatment of chronic kidney disease in adults with type 2 diabetes. This decision follows a study demonstrating a 20% reduction in the risk of kidney-related death for patients taking Ozempic. 12/11/2024 Novo Nordisk is partnering with the Sher-i-Kashmir Institute of Medical Sciences (SKIMS) to drive clinical research in India. The collaboration will focus on addressing critical medical needs in nephrology, rare diseases, cardiology, and obesity. 12/9/2024 Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s popular obesity drug, Wegovy. However, the deal still needs to be cleared by the U.S. Federal Trade Commission before it can be finalized. 12/6/2024 Novo Nordisk announced a major price reduction for two of its insulin products. Starting in January 2026, the list price of Fiasp will drop by 75%, while Tresiba will see a 72.2% reduction. Novo Nordisk will also discontinue unbranded versions of Tresiba by the end of 2025. 12/5/2024 Novo Nordisk announced a large investment of DKK 2.9 billion ($411 million) to construct a new quality control laboratory in Hillerød, Denmark. The new 53,000-square-meter facility is expected to be operational by 2027 and will be Novo Nordisk’s largest quality control investment to date. 12/3/2024 Novo Nordisk’s India team wants to launch the weight-loss drug Wegovy sooner than planned. They’re concerned about falling behind the company’s rival, Eli Lilly, whose similar drug Mounjaro is expected to launch next year. 11/27/2024 Health Canada has granted approval for Novo Nordisk’s weight-loss drug, Wegovy. Wegovy now becomes the first treatment in Canada to address both obesity and the risk of heart-related issues in adults with pre-existing cardiovascular disease. 5-10 Year Review Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment, and HGH, among others. Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s expansion towards treating other afflictions saw billions spent in acquisitions. The past decade has seen the following events: In 2015, Novo Nordisk announced a $400 million collaboration with Sanofi subsidiary Ablynx, to use its nanobody technology to develop a new drug. After an unsuccessful bid to acquire Ablynx in 2018, Novo Nordisk bought diabetes drug company Ziylo. 2020 saw Novo Nordisk buying Corvidia Therapeutics from AstraZeneca for its heart disease treatments. Novo Nordisk announced it would acquire Emisphere Technologies for $1.35 billion in December 2020, adding another diabetes pill to its catalog. In November 2021, Novo Nordisk acquired Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion. Intending to expand its sickle cell disease and rare blood disorders portfolio, 2022 saw Novo Nordisk buying Forma Therapeutics for $1.1 billion. Flush with Ozempic and Wegovy cash, Novo Nordisk bought Inversago Pharma for $1 billion, Embark Biotech for up to $500 million, ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion during 2023. To address expanding Ozempic and Wegovy demand, Novo Nordisk’s parent, Novo Holdings, bought NJ-based Catalent, a global provider of drug delivery systems, gene therapies, manufacturing, biologics, and other operations, in 2024. 2024 also saw the acquisitions of Cardior Pharmaceuticals for its cardiovascular treatment portfolio, and Austria’s Single use Support, a fluid management company. Fiscal Year (DEC) Price Revenues Net Income DKK (=US$0.15) DKK (=US$0.15) 2015 $29.04 107.927B/$16.19B 34.860B/$5.23B 2016 $17.93 111.780B/$16.76B 37.925B/$5.69B 2017 $26.83 111.696B/$16.75B 38.130B/$5.72B 2018 $23.03 111.831B/$16.77B 38.628B/$5.79B 2019 $28.94 122.021B/$18.30B 38.951B/$5.84B 2020 $34.92 126.946B/$19.04B 42.138B/$6.32B 2021 $56.00 140.800B/$21.12B 47.757B/$7.16B 2022 $67.67 176.954B/$26.54B 55.525B/$8.33B 2023 $103.45 232.261B/$34.84B 83.683B/$12.55B 2024 LTM (as of June) $142.74 258.003B/$38.70B 89.898B/$13.48B Key Drivers for Novo Nordisk’s Stock in the Future The obesity and weight-loss drug market is expected to his $100 billion by 2030. A more potent obesity treatment called CagriSema combines semaglutide, the active ingredient in Ozempic, with amylin and calcitonin receptor agonists. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood. Results for two late-stage FDA trials of the drug are expected by the end of 2024. Wegovy’s June 2024 approval for sales in China opens the door to a new market, which has hundreds of million prospective new customers from China’s burgeoning middle and upper class. New experimental obesity drug Amycretin, a single molecule that operates as a GLP-1 receptor agonist that reduces one’s appetite, is in phase-1 FDA trials. The new pill achieved a 13.1% average weight loss after 12 weeks, more than doubling the efficacy of Wegovy for the same time span. With the obesity drug market expected to reach $100 billion by 2030, genetic-based treatments currently in the R&D stage could become the next pharma golden ring. While some legal experts believe that the number of Ozempic lawsuits over gastroparesis and other afflictions, such as pancreatitis, kidney, and gallbladder issues, can reach as high as 20,000, Novo Nordisk is apparently confident it can reach a settlement that will allow it to continue its growth trajectory without impediment. Stock Price Prediction for 2025 Out of 11 Wall Street analysts, their consensus recommendation is “outperform/hold”, based on 5 buy, 2 outperform, 2 hold, and 2 sell. Their consensus 12-month target price for Novo Nordisk is $140.07, which is a 60.32% gain over today’s stock price. The 24/7 Wall Street 12-month projected target is a more conservative $124.20. This would be 42.15% above today’s price. Novo Nordisk’s Next 5 Years’ Outlook Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals require drugs that meet the following criteria: Sufficient efficacy to fulfill the medical needs of a large population of patients; Tolerable enough for prolonged patient treatment to obtain a significant and consistent therapeutic effect; Flexible enough to be prescribed to patients without an abundance of diagnostic testing or monitoring; Formulaically efficient enough to manufacture and distribute at scale. With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially larger market than the entirety of its European share. China’s middle and wealthy classes have multiplied exponentially as China’s GDP has grown. Obesity, heart diseases, and other ailments common in the West have escalated in China as diets and lifestyles adapted to mimic Western tastes and trends. Our price target for 2026 is $136.62. The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase-3 trials, these would presumably occur throughout 2025 and 2026. Therefore, CagriSema is likely to be cleared for public dissemination and ready for market by 2027. Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction in 32 weeks, over Wegovy. Our price target for 2027 is $153.01. Although Novo Nordisk’s pipeline of new drugs under FDA review targets obesity, its revamped product menu has expanded via acquisitions. Revenues from its HGH, estrogen replacement, and wound treatment products, as well as other diabetes variants, should all contribute to the bottom line with full production, marketing, and sales integration by 2028. We predict a price of $165.26. Obesity pill Amecrytin, which acts as an appetite suppressant without the effects of amphetamines, is presently in FDA phase-1 trials, but should be cleared for market and ready for distribution in 2029. Its weight-loss efficacy doubles that of Wegovy in shorter 3-month periods, and its pill configuration convenience should make it a hit prescription for doctors. Our price target is $186.74. Novo Nordisk Stock in 2030 Ozempic is an injection administered drug. R&D for a genetic based obesity drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals. With the obesity treatment market expected to hit $100 billion in 2030, even the announcement of a genetic-based drug ready to start FDA trials would generate significant buzz. With Novo Nordisk the current market leader, such an announcement in 2030 is not a stretch. Our target price is $192.34. Cumulatively, 24/7 Wall Street anticipates Novo Nordisk to appreciate 79% over the next 5 years. Year EPS P/E multiple Price 2025 $4.97 25 $124.20 2026 $5.46 25 $136.62 2027 $6.12 25 $153.01 2028 $6.61 25 $165.26 2029 $7.47 25 $186.74 2030 $7.69 25 $192.34 Get Ready To Retire (Sponsored) Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. Here’s how it works: 1. Answer SmartAsset advisor match quiz 2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles. 3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future Get started right here. The post Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St.. |
https://247wallst.com |
2024-12-27 06:30:39 |
Czytaj oryginał (ang.) |
| Better Buy: Eli Lilly vs. Novo Nordisk. |
It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson captured myriad headlines as each of these businesses played an integral role in the development of vaccines used to treat COVID-19. |
fool.com |
2024-12-26 12:15:00 |
Czytaj oryginał (ang.) |
| Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy? |
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NVO -1.51%) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success. |
fool.com |
2024-12-26 10:00:00 |
Czytaj oryginał (ang.) |
| CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field |
Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental CagriSema weight loss drug, and more. |
youtube.com |
2024-12-26 09:50:26 |
Czytaj oryginał (ang.) |